ArticleCancers2022

Comparative Effectiveness and Safety of Standard-Dose and Low-Dose Pembrolizumab in Patients with Non-Small-Cell Lung Cancer: A Multi-Institutional Cohort Study in Taiwan.

Kai-Cheng Chang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.